LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, bio-terrorism, cancer, and addiction, announced today groundbreaking results in animal trials for its drug candidate StatC against Avian Flu, Spanish Flu and Hong Kong Flu strains. Studies performed using StatC have shown results which are superior to TAMIFLU, the leading influenza antiviral (estimated market size in excess of $2.2 billion) drug distributed in the United States by Roche Pharmaceuticals. Specifically, the research found that Canopus BioPharma’s StatC is superior to TAMIFLU in preventing influenza in three different strains of the virus in mouse models.
